FDA Minds DTC “Reminder Ad” Increase, Seeks Better “Brief Summaries”
FDA is concerned that industry may be using "reminder ads" more frequently as a way to avoid including risk information in direct-to-consumer marketing
More from Archive
More from Pink Sheet
Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.
The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.